Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy
The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus. The present invention also relates to diagnostic assays for identifying and characterizing a strain of coronavirus as being one causing severe acute respiratory syndrome.
1. A method for screening for a potential anti-SARS antiviral agent, comprising the steps of:
(a) exposing SARS coronavirus-infected cells to a candidate compound;
(b) lysing the SARS coronavirus-infected cells;
(c) incubating virus particles or subtilisin-treated virions with a cAMP-dependent protein kinase substrate; and
(d) comparing cAMP dependent protein kinase activity to cells not exposed to the candidate compound.
2. The method of claim 1 , wherein inhibition of the cAMP-dependent protein kinase activity in the SARS coronavirus-infected cells indicates that the candidate compound has antiviral activity.
3. The method of claim 2 , wherein the candidate compound having antiviral activity inhibits SARS-coronavirus infectivity of a cell.
4. The method of claim 1 , wherein the virus particles or subtilisin-treated virions are incubated with the cAMP-dependent protein kinase substrate in the presence of an appropriate buffer.
5. The method of claim 1 , wherein the cAMP-dependent protein kinase substrate is Kemptide.
6. The method of claim 1 , wherein the cAMP dependent protein kinase activity is measured by counting radiolabelled ATP incorporation in the presence of the cAMP-dependent protein kinase substrate.
7. The method of claim 6 , wherein the cAMP-dependent protein kinase substrate is Kemptide.
8. The method of claim 6 , wherein reduction of the radiolabelled ATP incorporation within the cAMP-dependent protein kinase substrate indicates that the candidate compound has antiviral activity.
9. A method for screening for a potential anti-SARS antiviral agent, comprising the steps of:
(a) exposing SARS coronavirus-infected cells to a candidate compound;
(b) lysing the SARS coronavirus-infected cells; and
(c) comparing interactions between an ORF3a product and an ORF3b product to cells not exposed to the candidate compound.
10. The method of claim 9 , wherein decreased or inhibited interaction between the ORF3a product and the ORF3b product indicates that the candidate compound has antiviral activity.
11. The method of claim 9 , wherein the interactions are measured using a gel electrophoresis assay.
12. The method of claim 11 , wherein interacting products have a higher position on the gel electrophoresis assay than non-interacting products.
13. The method of claim 12 , wherein the interacting products indicates that the candidate compound does not inhibit or decrease the interactions between the ORF3a product and the ORF3b product.
14. The method of claim 9 , wherein the candidate compound having antiviral activity inhibits SARS-coronavirus infectivity of a cell.